Guggenheim analyst Jason Cassorla lowered the firm’s price target on Elevance Health (ELV) to $396 from $414 and keeps a Buy rating on the shares on recalibrated 2026 estimates following the company’s Q4 report.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health Earnings Call Flags Reset Before Rebound
- Elevance Health sees FY26 operating cash flow ‘at least’ $5.5B
- Elevance Health reports Q4 adjusted EPS $3.33, consensus $3.09
- Elevance Health sees FY26 adjusted EPS ‘at least’ $25.50, consensus $26.80
- Elevance Health sees FY26 revenue ‘low single digit decline’ y/y